The patent to which you are referring is defensive. It is not intended to be granted in it's current form.
Supporting clinical data from IONIC will allow IP protection to be obtained; there is precedent because of DARRT.
Ann: Veyonda and Opdivo IONIC Study First Patient Dosed, page-32
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
-0.017(14.8%) |
Mkt cap ! $28.63M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 9.8¢ | $70.79K | 680.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25356 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 240399 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |